Dr. Michael Z. Wang, M.D.
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Minnesota Medical School (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 2,464
Licensed in California since 2018, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: University of Minnesota Medical School
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
CA license A156280 (first issued 2018; current) · MN license 58486 -
Internal Medicine Physician
OH license 57.022590
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Golden State Dermatology Associates, Inc. (125 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 2,464
- Services billed
- 11,166
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 3,028 | 480 |
| Pathology examination of tissue using a microscope, intermediate complexity | 1,723 | 1,193 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,195 | 773 |
| Destruction of precancer skin growth, 1 growth | 827 | 592 |
| Established patient office or other outpatient visit, 30-39 minutes | 634 | 422 |
| Destruction of precancer skin growth, 15 or more growths | 521 | 315 |
| Destruction of skin growth, 1-14 growths | 465 | 308 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 355 | 242 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 146 | 131 |
| Biopsy of related skin growth, first growth | 130 | 125 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 54 payments worth $1,194 in total to this clinician.
| Genzyme Corporation | $244 |
|---|---|
| Novartis Pharmaceuticals Corporation | $193 |
| UCB, Inc. | $135 |
| Pfizer Inc. | $124 |
| Lilly USA, LLC | $93.23 |
| Galderma Laboratories, L.P. | $92.44 |
| AbbVie Inc. | $62.68 |
| Incyte Corporation | $58.63 |
| Food and Beverage | $1,194 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $52,435 in research payments for these studies, mostly to the institutions running them.
- Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
Sanofi US Services Inc. · Completed · NCT05991323 - A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK)
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.